Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Sell
27
XTNT Quote, Financials, Valuation and Earnings
Last price:
$0.41
Seasonality move
:
20.25%
Day range:
$0.35 - $0.38
52-week range:
$0.33 - $1.31
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.42x
P/B ratio:
1.09x
Volume:
209.2K
Avg. volume:
219.1K
1-year change:
-68.42%
Market cap:
$50M
Revenue:
$91.3M
EPS (TTM):
-$0.13
Analysts' Opinion
-
Consensus RatingXtant Medical Holdings has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Xtant Medical Holdings has an estimated upside of 525% from its current price of $0.36.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $0.36.
Fair Value
-
According to the consensus of 0 analysts, Xtant Medical Holdings has 525% upside to fair value with a price target of -- per share.
XTNT vs. S&P 500
-
Over the past 5 trading days, Xtant Medical Holdings has overperformed the S&P 500 by 0.6% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Xtant Medical Holdings does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Xtant Medical Holdings has grown year-over-year revenues for 11 quarters straight. In the most recent quarter Xtant Medical Holdings reported revenues of $27.9M.
Earnings Growth
-
Xtant Medical Holdings has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Xtant Medical Holdings reported earnings per share of -$0.04.
Enterprise value:
78.2M
EV / Invested capital:
0.97x
Price / LTM sales:
0.42x
EV / EBIT:
--
EV / Revenue:
0.69x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-4.53x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
48.65x
Gross Profit (TTM):
$69.3M
Return On Assets:
-18.59%
Net Income Margin (TTM):
-15.45%
Return On Equity:
-35.98%
Return On Invested Capital:
-22.96%
Operating Margin:
-13.52%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $56.7M | $78.5M | $113.9M | $25M | $27.9M | |
| Gross Profit | $31.5M | $46.6M | $69.3M | $15.3M | $16.3M | |
| Operating Income | -$6.9M | -$8.1M | -$14M | -$3.4M | -$3.8M | |
| EBITDA | -$5.7M | $5.6M | -$8.9M | $8.6M | -$2.7M | |
| Diluted EPS | -$0.11 | $0.01 | -$0.13 | $0.07 | -$0.04 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $32.4M | $45.6M | $45.1M | $64.1M | $71.4M | |
| Total Assets | $42.4M | $55.8M | $56M | $92M | $98.9M | |
| Current Liabilities | $9.3M | $10.4M | $11.4M | $21.9M | $33.7M | |
| Total Liabilities | $90.4M | $23.2M | $23.3M | $37.3M | $53.2M | |
| Total Equity | -$48M | $32.6M | $32.8M | $54.7M | $45.7M | |
| Total Debt | $79.6M | $15.2M | $12.7M | $21.2M | $34.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$2.6M | -$10.9M | -$13.5M | -$3.8M | -$1.7M | |
| Cash From Investing | -$1.7M | -$22.9M | -$5.5M | -$4.7M | -$2M | |
| Cash From Financing | $3.4M | $25M | $17.3M | $12.8M | $5.3M | |
| Free Cash Flow | -$4.6M | -$12.4M | -$17.3M | -$4.1M | -$3.8M | |
XTNT
Sector
Market Cap
$50M
$43.9M
Price % of 52-Week High
27.48%
45.73%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-68.42%
-29.11%
Beta (5-Year)
0.357
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$0.36
200-day SMA
Sell
Level
$0.69
Bollinger Bands (100)
Sell
Level
0.44 - 0.66
Chaikin Money Flow
Sell
Level
-202.8M
20-day SMA
Sell
Level
$0.38
Relative Strength Index (RSI14)
Sell
Level
27.25
ADX Line
Buy
Level
9.55
Williams %R
Neutral
Level
-67.4157
50-day SMA
Sell
Level
$0.47
MACD (12, 26)
Sell
Level
-0.03
25-day Aroon Oscillator
Sell
Level
-72
On Balance Volume
Neutral
Level
457.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.0617)
Buy
CA Score
(Annual)
Level (0.3898)
Sell
Beneish M-Score
(Annual)
Level (-0.5477)
Sell
Momentum Score
Level (2)
Buy
Ohlson Score
Level (-6.6409)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the US.
Stock Forecast FAQ
In the current month, XTNT has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The XTNT average analyst price target in the past 3 months is --.
-
Where Will Xtant Medical Holdings Stock Be In 1 Year?
According to analysts, the consensus estimate is that Xtant Medical Holdings share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Xtant Medical Holdings?
Analysts are divided on their view about Xtant Medical Holdings share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Xtant Medical Holdings is a Sell and believe this share price will drop from its current level to --.
-
What Is Xtant Medical Holdings's Price Target?
The price target for Xtant Medical Holdings over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is XTNT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Xtant Medical Holdings is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of XTNT?
You can purchase shares of Xtant Medical Holdings via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Xtant Medical Holdings shares.
-
What Is The Xtant Medical Holdings Share Price Today?
Xtant Medical Holdings was last trading at $0.41 per share. This represents the most recent stock quote for Xtant Medical Holdings. Yesterday, Xtant Medical Holdings closed at $0.36 per share.
-
How To Buy Xtant Medical Holdings Stock Online?
In order to purchase Xtant Medical Holdings stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is up 3.65% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 4.9% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 4.4% over the past day.
